tiprankstipranks
Advertisement
Advertisement
Nektar’s Phase 3 Eczema Bet: What Rezpegaldesleukin Could Mean for NKTR Stock
PremiumCompany AnnouncementsNektar’s Phase 3 Eczema Bet: What Rezpegaldesleukin Could Mean for NKTR Stock
19d ago
Canaccord sees potential Apogee buyout as ‘huge win’ for sector
Premium
The Fly
Canaccord sees potential Apogee buyout as ‘huge win’ for sector
1M ago
Nektar Stockholders Approve Governance and Incentive Plan Changes
Premium
Company Announcements
Nektar Stockholders Approve Governance and Incentive Plan Changes
2M ago
Nektar Therapeutics Charts Aggressive Path With REZPEG
PremiumCompany AnnouncementsNektar Therapeutics Charts Aggressive Path With REZPEG
3M ago
Nektar Therapeutics Establishes New Equity Distribution Agreement
Premium
Company Announcements
Nektar Therapeutics Establishes New Equity Distribution Agreement
3M ago
Julian Harrison Reiterates Buy on Nektar, Citing Robust REZPEG Program and Strong Balance Sheet; Maintains $178 Price Target
Premium
Ratings
Julian Harrison Reiterates Buy on Nektar, Citing Robust REZPEG Program and Strong Balance Sheet; Maintains $178 Price Target
3M ago
Nektar Therapeutics Prices Upsized Public Equity Offering
PremiumCompany AnnouncementsNektar Therapeutics Prices Upsized Public Equity Offering
3M ago
Nektar 3.5M share Secondary priced at $92.00
Premium
The Fly
Nektar 3.5M share Secondary priced at $92.00
4M ago
Nektar price target raised to $95 from $70 at Wedbush
Premium
The Fly
Nektar price target raised to $95 from $70 at Wedbush
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100